PAOG Explores Cannabis Respiratory Research Partne
Post# of 35484
(Total Views: 69)
Posted On: 08/14/2020 3:18:48 PM
PAOG Explores Cannabis Respiratory Research Partnership in Israel
Sandusky, Ohio--(Newsfile Corp) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company is aggressively pursuing international research partnerships to advance its cannabis respiratory treatment development.
The company recently revealed research partnership developments in Puerto Rico where Congresswoman Jenniffer González Colón and Florida Senator Marco Rubio recently introduced legislation to position Puerto Rico as a global production center of medical equipment and drugs.
Israel is recognized as one of the leading cannabis research centers in the world. Parallel to PAOG's own research on its proprietary cannabis extract for the treatment of COVID-19, a study in Israel was recently released with findings that turpentines in cannabis showed efficacy in treating COVID-19.
PAOG recently acquired the proprietary formulations derived from a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." The formulation tradename is RespRx.
The RespRx CBD Biopharma treatment targets multiple respiratory-related diseases to include COPD and COVID-19.
A paper on the results of the study was published and well-received, given the potential impact on this large market. WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
Sandusky, Ohio--(Newsfile Corp) - PAO Group, Inc. (OTC Pink: PAOG) today announced the company is aggressively pursuing international research partnerships to advance its cannabis respiratory treatment development.
The company recently revealed research partnership developments in Puerto Rico where Congresswoman Jenniffer González Colón and Florida Senator Marco Rubio recently introduced legislation to position Puerto Rico as a global production center of medical equipment and drugs.
Israel is recognized as one of the leading cannabis research centers in the world. Parallel to PAOG's own research on its proprietary cannabis extract for the treatment of COVID-19, a study in Israel was recently released with findings that turpentines in cannabis showed efficacy in treating COVID-19.
PAOG recently acquired the proprietary formulations derived from a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled, "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT." The formulation tradename is RespRx.
The RespRx CBD Biopharma treatment targets multiple respiratory-related diseases to include COPD and COVID-19.
A paper on the results of the study was published and well-received, given the potential impact on this large market. WHO estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.
(0)
(0)Scroll down for more posts ▼